Michael Mancenido, DO
Infectious Disease · Rochester, NYNPI 1669536496
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,030 of the $32,141 with a category attached, or 77.9%. Viiv Healthcare Company accounts for 81.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $23,270 and has fallen 98.6% since, to $321 in 2025. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $378.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$26K
- Janssen Products, LP$5K
- Gilead$874
- Johnson & Johnson$142
- Astellas Pharma US Inc$132
- AbbVie$33
- plus $72 from 3 others
What the payments were for
- Consulting fees$2,7609%
- Speaking & faculty fees$25,03078%
- Travel & lodging$1,4795%
- Food & beverage$2,6778%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 39 | $26,202 |
| Janssen Products, LP | 5 | $4,686 |
| Gilead | 24 | $874 |
| Johnson & Johnson | 8 | $142 |
| Astellas Pharma US Inc | 3 | $132 |
| AbbVie | 2 | $33 |
| Insmed, Inc. | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,141 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $61,535 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $41,567 |
| PrezistaDarunavir | 11 | $22,532 |
| CeftriaxoneCeftriaxone Sodium | 29 | $3,660 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 19 | $1,874 |
| Vancomycin Hcl | 41 | $1,820 |
| Lamotrigine ErLamotrigine | 11 | $1,554 |
| Cefepime Hcl | 11 | $875 |
| Cefazolin Sodium | 17 | $747 |
| Sodium Chloride0.9 % Sodium Chloride | 54 | $716 |
| Doxycycline Hyclate | 31 | $686 |
| Cefadroxil | 15 | $549 |
| Pitavastatin Calcium | 11 | $396 |
| Ciprofloxacin Hcl | 23 | $309 |
| Doxycycline Monohydrate | 11 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $874 | $103,10226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 799 infectious disease providers in New York.
Other infectious disease in Rochester
- Ann FalseyRochester$135K
- Edward WalshRochester$86K
- Emil LeshoRochester$68K
- William ValentiRochester$22K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.